New pharmacological strategies to increase cGMP

Alessia Buglioni, John C Jr. Burnett

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The intracellular nucleotide cyclic guanosine monophosphate (cGMP) is found in many human organ tissues. Its concentration increases in response to the activation of receptor enzymes called guanylyl cyclases (GCs). Different ligands bind GCs, generating the second messenger cGMP, which in turn leads to a variety of biological actions. A deficit or dysfunction of this pathway at the cardiac, vascular, and renal levels manifests in cardiovascular diseases such as heart failure, arterial hypertension, and pulmonary arterial hypertension. An impairment of the cGMP pathway also may be involved in the pathogenesis of obesity as well as dementia. Therefore, agents enhancing the generation of cGMP for the treatment of these conditions have been intensively studied. Some have already been approved, and others are currently under investigation. This review discusses the potential of novel drugs directly or indirectly targeting cGMP as well as the progress of research to date.

Original languageEnglish (US)
Pages (from-to)229-243
Number of pages15
JournalAnnual Review of Medicine
Volume67
DOIs
StatePublished - Jan 14 2016

Fingerprint

Cyclic GMP
Pharmacology
Guanylate Cyclase
Enzyme Activation
Second Messenger Systems
Nucleotides
Pulmonary Hypertension
Blood Vessels
Dementia
Cardiovascular Diseases
Heart Failure
Obesity
Chemical activation
Tissue
Ligands
Hypertension
Kidney
Enzymes
Research
Pharmaceutical Preparations

Keywords

  • Cardiometabolic disease
  • Guanylyl cyclase
  • Natriuretic peptides
  • NEP
  • NO
  • PDEs

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

New pharmacological strategies to increase cGMP. / Buglioni, Alessia; Burnett, John C Jr.

In: Annual Review of Medicine, Vol. 67, 14.01.2016, p. 229-243.

Research output: Contribution to journalArticle

@article{05294a93dd9b41b49db9b50f25bfb4a1,
title = "New pharmacological strategies to increase cGMP",
abstract = "The intracellular nucleotide cyclic guanosine monophosphate (cGMP) is found in many human organ tissues. Its concentration increases in response to the activation of receptor enzymes called guanylyl cyclases (GCs). Different ligands bind GCs, generating the second messenger cGMP, which in turn leads to a variety of biological actions. A deficit or dysfunction of this pathway at the cardiac, vascular, and renal levels manifests in cardiovascular diseases such as heart failure, arterial hypertension, and pulmonary arterial hypertension. An impairment of the cGMP pathway also may be involved in the pathogenesis of obesity as well as dementia. Therefore, agents enhancing the generation of cGMP for the treatment of these conditions have been intensively studied. Some have already been approved, and others are currently under investigation. This review discusses the potential of novel drugs directly or indirectly targeting cGMP as well as the progress of research to date.",
keywords = "Cardiometabolic disease, Guanylyl cyclase, Natriuretic peptides, NEP, NO, PDEs",
author = "Alessia Buglioni and Burnett, {John C Jr.}",
year = "2016",
month = "1",
day = "14",
doi = "10.1146/annurev-med-052914-091923",
language = "English (US)",
volume = "67",
pages = "229--243",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - New pharmacological strategies to increase cGMP

AU - Buglioni, Alessia

AU - Burnett, John C Jr.

PY - 2016/1/14

Y1 - 2016/1/14

N2 - The intracellular nucleotide cyclic guanosine monophosphate (cGMP) is found in many human organ tissues. Its concentration increases in response to the activation of receptor enzymes called guanylyl cyclases (GCs). Different ligands bind GCs, generating the second messenger cGMP, which in turn leads to a variety of biological actions. A deficit or dysfunction of this pathway at the cardiac, vascular, and renal levels manifests in cardiovascular diseases such as heart failure, arterial hypertension, and pulmonary arterial hypertension. An impairment of the cGMP pathway also may be involved in the pathogenesis of obesity as well as dementia. Therefore, agents enhancing the generation of cGMP for the treatment of these conditions have been intensively studied. Some have already been approved, and others are currently under investigation. This review discusses the potential of novel drugs directly or indirectly targeting cGMP as well as the progress of research to date.

AB - The intracellular nucleotide cyclic guanosine monophosphate (cGMP) is found in many human organ tissues. Its concentration increases in response to the activation of receptor enzymes called guanylyl cyclases (GCs). Different ligands bind GCs, generating the second messenger cGMP, which in turn leads to a variety of biological actions. A deficit or dysfunction of this pathway at the cardiac, vascular, and renal levels manifests in cardiovascular diseases such as heart failure, arterial hypertension, and pulmonary arterial hypertension. An impairment of the cGMP pathway also may be involved in the pathogenesis of obesity as well as dementia. Therefore, agents enhancing the generation of cGMP for the treatment of these conditions have been intensively studied. Some have already been approved, and others are currently under investigation. This review discusses the potential of novel drugs directly or indirectly targeting cGMP as well as the progress of research to date.

KW - Cardiometabolic disease

KW - Guanylyl cyclase

KW - Natriuretic peptides

KW - NEP

KW - NO

KW - PDEs

UR - http://www.scopus.com/inward/record.url?scp=84954545683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954545683&partnerID=8YFLogxK

U2 - 10.1146/annurev-med-052914-091923

DO - 10.1146/annurev-med-052914-091923

M3 - Article

C2 - 26473417

AN - SCOPUS:84954545683

VL - 67

SP - 229

EP - 243

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -